JNJ · News · 20260914N
Guidance and Outlook
JOHNSON & JOHNSON · 2026-09-14 · Importance 44 · Surprise 58 · In source text
J&J executives said the company remains on track to deliver double-digit growth through the end of the decade. Management expects its medicines portfolio, medical devices and pipeline programs to offset biosimilar competition to STELARA. The reported outlook indicates continued growth despite anticipated erosion from STELARA biosimilars, although no specific revenue or margin targets were provided in the digest.
Key facts
- Johnson & Johnson executives said the company remains on track to grow through biosimilar competition for STELARA and is targeting double-digit growth through the end of the decade. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | Johnson & Johnson executives said the company remains on track to grow through biosimilar competition for STELARA and is targeting… |